BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...$11 million in series A funding. TARGETSC5a – Complement 5a BC Staff Tecfidera, dimethyl fumarate (bg-12, BG00012) Avacopan (CCX168, C5aR...
BioCentury | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

...2020, U.S. IND submissions are slated for TJ210 and TJX7, which are in-house antibodies against C5AR1...
...C5AR1 (C5AR; CD88) - Complement receptor 5A; CXCL13 - Chemokine CXC motif ligand 13 Hongjiang Li, Staff Writer I-Mab Biopharma Complement receptor 5A (C5AR1) (C5AR) (CD88) Chemokine...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...for Myovant" ). After market hours Monday, ChemoCentryx reported that avacopan, an oral inhibitor of C5AR1...
...OTCQX:FSNUY) and Vifor Pharma Ltd. (SIX:VIFN). Targets: C3 - Complement 3; C5AR1 (C5AR; CD88) - Complement receptor 5A...
...B7-H1; CD274) - Programmed cell death 1 ligand 1 Paul Bonanos, Associate Editor Avacopan (CCX168, C5aR inhibitor) ChemoCentryx Inc. Complement receptor 5A (C5AR1) (C5AR) (CD88) Vifor...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...Phase III ADVOCATE trial to treat patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. The small molecule complement receptor 5a...
...of its Nov. 30 PDUFA date. Elizabeth S. Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

...oncology candidates: monalizumab, a mAb against NK cell checkpoint protein NKG2A; anti-KIR3DL2 mAb IPH4102; and anti-C5AR1...
...preclinical pipeline, including bringing anti-CD73 mAb IPH5301 to the clinic. Targets: C5AR1 (C5AR; CD88) - Complement receptor 5A...
...NKG2A) (CD159a) (KLRC1) Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K) Ecto-5'-nucleotidase (CD73) (NT5E) Complement receptor 5A (C5AR1) (C5AR) (CD88) IPH5301...
BioCentury | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

...lost $2.10 (19%) to $8.98 in afternoon trading Wednesday. ChemoCentryx is developing the small molecule C5aR...
...IIb AURORA study to treat hidradenitis suppurativa. Targets: C5a - complement 5a; C5aR (CD88) - complement receptor 5a...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...Complement component 1 q subcomponent (C1q) Annexon Biosciences Inc. ANX005 Undisclosed Preclin Complement receptor 5A (C5AR1; C5AR; CD88...
...C5a by blocking its receptor, C5AR1 (see “Complementary ALS Play” ). When C5a binds to C5AR1...
...University, Stanford, Calif. Targets C1q - Complement component 1 q subcomponent C5AR1 (C5AR; CD88) - Complement receptor 5A...
BioCentury | Jan 25, 2019
Clinical News

ChemoCentryx, Vifor Fresenius to seek full approval of avacopan next year

...III ADVOCATE trial of avacopan in the indication. The small molecule inhibits complement receptor 5a (C5AR1; C5AR; CD88...
...Product: Avacopan (CCX168) Business: Inflammation Jennie Walters Avacopan (CCX168, C5aR inhibitor) ChemoCentryx Inc. Fresenius SE & Co. KGaA Vifor Pharma Ltd. Complement receptor 5A (C5AR1) (C5AR) (CD88)...
BioCentury | Nov 30, 2018
Company News

I-Mab gains Chinese rights to MorphoSys' MOR210

...milestones, plus tiered, mid single-digit royalties. MOR210 is an antibody directed against complement receptor 5A (C5AR1; C5AR; CD88...
...cancer. MorphoSys AG (Xetra:MOR; NASDAQ:MOR), Planegg, Germany I-Mab Biopharma, Shanghai, China Business: Cancer Shannon Lehnbeuter MOR210 I-Mab Biopharma MorphoSys AG Complement receptor 5A (C5AR1) (C5AR) (CD88)...
BioCentury | Jun 15, 2018
Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

...candidate to treat hidradenitis suppurativa this year. Avacopan is a small molecule complement receptor 5A (C5AR1; C5AR; CD88...
...Leon Avacopan (CCX168, C5aR inhibitor) CCX140 ChemoCentryx Inc. Fresenius SE & Co. KGaA Vifor Pharma Ltd. CC chemokine receptor 2 (CCR2) (CD192) Complement receptor 5A (C5AR1) (C5AR) (CD88)...
Items per page:
1 - 10 of 59